2025-10-30 - Analysis Report
Okay, here's an analysis of Merck & Co. Inc. (MRK) based on the provided data, structured as requested.

**0. Report Summary**

*   **Stock Ticker:** MRK
*   **Company Name:** Merck & Co. Inc.
*   **Analysis Date:** October 29, 2025

**1. Performance vs. S&P 500 (VOO)**

*   **MRK Cumulative Return:** 2.49%
*   **VOO Cumulative Return:** 104.04%
*   **Absolute Divergence:** -95.6%
*   **Relative Divergence:** 6.5%

**Analysis:** MRK has significantly underperformed the S&P 500 over the period analyzed. The relative divergence of 6.5% indicates that MRK's underperformance is near the lower end of its historical range compared to VOO.

**Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that develops and markets medicines and vaccines to address unmet medical needs.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD     | Alpha     | Beta   | Cap(B)  |
| :----------- | :------ | :------ | :-------- | :----- | :------ |
| 2015-2017  | 1.0%    | 68.5%   | -28.0%    | 0.0    | 134.1   |
| 2016-2018  | 36.0%   | 69.8%   | 21.0%     | -0.0   | 182.1   |
| 2017-2019  | 40.0%   | 69.8%   | 18.0%     | 0.3    | 216.7   |
| 2018-2020  | 16.0%   | 79.6%   | -8.0%     | 0.3    | 194.9   |
| 2019-2021  | 2.0%    | 79.6%   | -44.0%    | 0.7    | 191.4   |
| 2020-2022  | 15.0%   | 79.6%   | 16.0%     | 0.7    | 277.1   |
| 2021-2023  | 33.0%   | 79.6%   | 31.0%     | 0.3    | 272.3   |
| 2022-2024  | -4.0%   | 79.6%   | -25.0%    | 0.2    | 248.4   |
| 2023-2025  | -47.0%  | 71.5%   | -115.0%   | 1.6    | 216.5   |

**Analysis:**
*   **CAGR:**  The Compound Annual Growth Rate varies significantly, with some periods showing strong growth (e.g., 2016-2019) and others showing negative growth (e.g., 2022-2025). The recent negative CAGR is concerning.
*   **MDD:** The Maximum Drawdown is consistently high, indicating substantial risk and volatility in MRK's returns.
*   **Alpha:**  Alpha fluctuates, with some periods showing positive alpha (outperformance relative to the benchmark) and others showing negative alpha (underperformance).  The most recent period (2023-2025) has a significantly negative alpha.
*   **Beta:** Beta values are generally low, suggesting MRK is less sensitive to market movements than the S&P 500. However, the recent increase in Beta to 1.6 in the 2023-2025 period is notable, indicating increased correlation with the market and potentially higher volatility.
*   **Cap(B):** The market capitalization is very high ($216.5 ~ $277.1 billion).

**2. Recent Stock Price Movement**

*   **Current Price:** 86.69
*   **Last Market Data:** Price: 86.715, Previous Close: 87.03, Change: -0.36
*   **5-Day Moving Average:** 87.394
*   **20-Day Moving Average:** 86.9157
*   **60-Day Moving Average:** 84.0548

**Analysis:** The stock price is currently below its 5-day and 20-day moving averages, which suggests a potential short-term downward trend. However, it's above the 60-day moving average, indicating a potentially stronger longer-term trend. The slight price decrease in the last market data (-0.36) is not significant enough to indicate a major volatility event.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 51.60 (Neutral)
*   **PPO:** 0.0608 (Neutral)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (35 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Divergence Change:** 0.5 (+) (Short-term increase)
*   **Expected Return:** -106.9% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests a "High Investment Recommended" rating, seemingly contradicting other indicators.
*   The RSI is near the middle (50), indicating neither overbought nor oversold conditions.
*   The PPO is also close to zero, suggesting that the short-term and long-term moving averages are relatively close.
*   The Hybrid Signal suggests buying the stock fully with all of the current money(Cash 0%), even suggesting invest monthly. This signal seems to be derived from the MRI.
*   The short-term increase in relative divergence is a positive sign, potentially indicating a recent upward momentum.
*   The significantly negative Expected Return (-106.9%) is a major red flag. It indicates that, based on current trends, the stock is expected to drastically underperform the S&P 500 over a long-term investment horizon.

**4. Recent News & Significant Events**

*   **Positive:** Keytruda wins EU approval for first-line head and neck cancer.
*   **Negative:** Phase 3 liver cancer trial closed after missing overall survival endpoint.
*   **Neutral/Mixed:** Other news items relate to analyst opinions on other stocks and general earnings reports, which don't directly impact MRK.

**Analysis:**  The news is mixed. The Keytruda approval is positive and could boost revenue. However, the failed liver cancer trial is a setback and may negatively impact investor sentiment.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.00)
*   **Target Price:** Average: 101.84 / High: 137.00 / Low: 82.00

**Analysis:** Analysts, on average, have a "Buy" rating and a target price significantly higher than the current price. This suggests they believe the stock is undervalued.  However, note the wide range in target prices, indicating uncertainty. It is not possible to know the recent rating changes because of absence of data.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
| :--------- | :---- | :--------- |
| 2025-08-05 | 1.76  | 15.81 B$   |
| 2025-05-02 | 2.01  | 15.53 B$   |
| 2024-11-06 | 1.25  | 16.66 B$   |
| 2024-08-05 | 2.15  | 16.11 B$   |
| 2025-08-05 | 2.15  | 16.11 B$   |

**Analysis:**  The EPS has fluctuated over the past year, with a recent drop in the most recent report. Revenue also shows some volatility. There's no clear upward or downward trend in either EPS or Revenue, however, most recent earnings reports shows lower than previous.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| :----------- | :--------- | :-------------- |
| 2025-06-30 | $15.81B   | 77.50%         |
| 2025-03-31 | $15.53B   | 77.98%         |
| 2024-12-31 | $15.62B   | 75.50%         |
| 2024-09-30 | $16.66B   | 75.51%         |
| 2024-06-30 | $16.11B   | 76.76%         |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
| :----------- | :---------- | :------- |
| 2025-06-30 | $48.99B    | 9.04%    |
| 2025-03-31 | $48.34B    | 10.51%   |
| 2024-12-31 | $46.31B    | 8.08%    |
| 2024-09-30 | $44.50B    | 7.09%    |
| 2024-06-30 | $43.58B    | 12.52%   |

**Analysis:** Revenue has been relatively stable over the past five quarters. Profit margins are very high, indicating strong pricing power.  Equity has been steadily increasing, which is a positive sign. ROE has fluctuated, with a recent decrease. The overall financial health seems strong based on these metrics.

**7. Overall Analysis and Recommendations**

Merck & Co. Inc. presents a mixed picture. While the company has a strong financial base, high profit margins, and positive analyst ratings, there are several concerning factors:

*   **Significant Underperformance:** The stock has significantly underperformed the S&P 500.
*   **Negative Expected Return:** The projected long-term underperformance is a major concern.
*   **Recent Earnings and Financial Data:** Recent earnings showed slight downward trend compare to previous reports.
*   **Mixed News:** While the Keytruda approval is positive, the failed liver cancer trial is a setback.

**Recommendation:**

The data suggests caution. While analysts are generally positive, the quantitative indicators paint a less optimistic picture. Investors should carefully consider the potential for continued underperformance before investing. The high MRI is an outlier compared to other metrics. While accumulating gradually or waiting to invest at more opportune times, it would be wise to examine the reasons for the underperformance.
